At a glance
ClinicalIndex Comparison RecordN/ACompleted· 205 enrolled
Drug / intervention
Resolute Onyx™ Zotarolimus-Eluting Coronary Stent Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
In Brief
A clinical study evaluating Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System for Coronary Artery Disease. Completed, enrolled 205 participants across 25 sites in 4 countries.
Detailed Summary
To observe the continued performance of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in a real-world more-comer population. To collect data on the safety and efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in bifurcated lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesBelgium, France, Slovakia, United States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJul 2018
Primary CompletionNov 2020
Study CompletionSep 2022
TodayJul 2026
First PostedJul 12, 2018
Enrollment StartMay 14, 2018
Primary CompletionNov 4, 2020
Study CompletionSep 28, 2022
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.0 years ago
Interventions
Resolute Onyx™ Zotarolimus-Eluting Coronary Stent Systemdevice
Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 5.0 mm